title: [Acral erythema occurring after didanosine (Videx) therapy].
authors.affiliation: Service de Dermatologie, Hôpital Pasteur, Cherbourg.
authors.forename: S
authors.initials: S
authors.lastname: Pedailles
authors.forename: V
authors.initials: V
authors.lastname: Launay
authors.forename: M
authors.initials: M
authors.lastname: Surbled
authors.forename: C
authors.initials: C
authors.lastname: Sentias
authors.forename: A
authors.initials: A
authors.lastname: Bazin
mesh_terms: D000328:Adult; D016049:Didanosine / Q000009:adverse effects* / Q000627:therapeutic use; D004890:Erythema / Q000139:chemically induced*; D005533:Foot Dermatoses / Q000139:chemically induced*; D015658:HIV Infections / Q000188:drug therapy; D006229:Hand Dermatoses / Q000139:chemically induced*; D006801:Humans; D008297:Male; D011358:Product Surveillance, Postmarketing
chemical_list: D016049:Didanosine
vernacular_title: Erythème acral survenant après prise de didanosine (Videx).